Related Experiment Video

Updated: Jul 15, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Angiotensin-converting enzyme inhibitors and coronary heart disease prevention

Richard Donnelly1, Gillian Manning

  • 1University of Nottingham Medical School, Derby City General Hospital, Derby, DE22 3DT, UK. richard.donnelly@nottingham.ac.uk

Journal of the Renin-Angiotensin-Aldosterone System : JRAAS
|May 10, 2007
PubMed

Insights

Angiotensin-converting enzyme (ACE) inhibitors significantly benefit secondary prevention of coronary artery disease (CAD). However, unexplained trial differences highlight the need for further research into ACE inhibitor mechanisms and clinical interpretation.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Large randomized controlled trials demonstrate that angiotensin-converting enzyme (ACE) inhibitors improve coronary heart disease (CHD) outcomes across diverse patient groups.
  • ACE inhibitors are effective in primary and secondary prevention, in patients with and without left ventricular dysfunction, and in both hypertensive and non-hypertensive individuals.

Purpose of the Study:

  • To review and compare findings from major trials of ACE inhibitors in patients with established coronary artery disease (CAD).
  • To analyze the underlying mechanisms and clinical significance of ACE inhibitor therapy in secondary CAD prevention, addressing unexplained inter-trial variations.

Main Methods:

  • An updated meta-regression analysis of five major trials (EUROPA, INVEST, ACTION, PEACE, CAMELOT) in patients with established CAD.
  • Comparative analysis of clinical outcomes, baseline cardiovascular risk, blood pressure changes, and trial designs.

Main Results:

  • ACE inhibitor therapy shows clear benefits in secondary prevention of CAD.
  • Significant unexplained differences exist between trials regarding clinical outcomes, with perindopril and ramipril showing the largest reductions in primary endpoints, while trandolapril and quinapril had no significant effect on survival or recurrent CAD events.

Conclusions:

  • ACE inhibitors are valuable for secondary CAD prevention, but variations in efficacy necessitate further investigation.
  • Understanding the mechanisms behind these inter-trial differences is crucial for optimizing clinical interpretation and patient management.

More Related Videos

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...